BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/24/2022 8:01:57 AM | Browse: 395 | Download: 874
 |
Received |
|
2022-07-03 06:35 |
|
Peer-Review Started |
|
2022-07-03 06:39 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-22 00:57 |
|
Revised |
|
2022-09-17 06:58 |
|
Second Decision |
|
2022-10-24 03:56 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-10-28 22:04 |
|
Articles in Press |
|
2022-10-28 22:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-11-17 14:37 |
|
Publish the Manuscript Online |
|
2022-11-24 08:01 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Abdulbaril Olagunju, Naser Yamani, Dorothy Kenny, Martina Mookadam, Farouk Mookadam and Samuel Unzek |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdulbaril Olagunju, MD, Doctor, Doctor, Internal medicine, Creighton University School of Medicine, 350 W Thomas Road, Phoenix, AZ 85013, United States. ab.dapoola@gmail.com |
| Key Words |
Metabolic syndrome; Sodium-glucose cotransporter 2 inhibitors; Dapagliflozin; Empagliflozin; Cardiovascular disease |
| Core Tip |
This meta-analysis of randomized, placebo-controlled trials aimed to evaluate the impact of dapagliglozin and empagliflozin on metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Panel III. In doing so, it highlighted a statistically significant improvement in fasting plasma glucose, systolic blood pressure and waist circumference. The effect of dapagliflozin and empagliflozin on high-density lipoprotein cholesterol was similar to that of placebo. In addition to its primary aim, this study also highlighted an improvement in other cardiometabolic parameters including hemoglobin A1C, uric acid and body weight in patients that received dapagliflozin and empagliflozin. |
| Publish Date |
2022-11-24 08:01 |
| Citation |
Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(10): 599-616 |
| URL |
https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v14.i11.599 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
